GlassScriptPhysician profile
Donna Michelle Capps
NPI 1578665444
$2,313.72
in general payments reported to CMS, 2019-2025
24 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $60.22 · 2021: $193 · 2022: $233 · 2023: $435 · 2024: $671 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $502.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $365.92 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $187.66 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $161.72 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $123.93 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $113.73 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.36 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $88.66 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $72.75 | 2024-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $67.48 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $60.71 | 2021-2023 | Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $60.29 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.70 | 2020-2025 | Xifaxan |
| Medtronic, INC. | $52.44 | 2024 | Intellis Adaptivestim |
| Sumitomo Pharma America, INC. | $44.91 | 2025 | Gemtesa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $44.73 | 2021-2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $37.18 | 2023 | Quviviq |
| Viatris Specialty LLC | $35.68 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $35.31 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $27.13 | 2021-2022 | |
| Corium, LLC | $22.78 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $17.77 | 2019 | |
| Mylan Specialty L.P. | $15.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Capps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.